Calumet
Calumet's revenue fell 1.2% to $4.1 billion in fiscal 2025. Its operating margin was 2.6%, up from 0.2% a year earlier. Free cash flow was $57 million. The diluted share count rose 4.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Calumet does
Calumet makes specialty products and renewable fuels, and sells them to consumer and industrial customers across North America. It is based in Indianapolis, Indiana and runs twelve facilities. Its specialty products include solvents, waxes, lubricating oils, white oils, petrolatums and gels, which its customers use as raw materials for other products. It also sells high-performance motor oils and fuel products under the Royal Purple, Bel-Ray and TruFuel brands.
It reports three segments plus corporate costs. Specialty Products and Solutions makes and markets the specialty products. Performance Brands blends, packages and markets the branded products. Montana/Renewables has two plants: Montana Renewables turns renewable feedstocks into renewable diesel, sustainable aviation fuel and renewable naphtha, and a specialty asphalt plant turns Canadian crude oil into gasoline, diesel, jet fuel and specialty asphalt for local markets.
Calumet says the Montana/Renewables segment produced about 83.6% of its gross profit from continuing operations in 2025, and Specialty Products and Solutions about 40.6%. It says it passes higher feedstock costs on to its specialty products customers. It plans an expansion of the Montana Renewables plant.
Its biggest risks, as it describes them
- Swings in the prices of crude oil and other commodities it buys and sells, which can narrow its margins.
- Relying on outside pipelines to move its raw materials and products.
- Accidents and shutdowns at its plants, including time out for maintenance, that cut revenue.
- Strong competition in each of its markets.
- Writing down the value of its plants or goodwill if they prove worth less than recorded.
Income statement
Calumet lost money in fiscal 2025: a net loss of $34 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | 35 | 8 | 38 | 125 |
| Debt incl. finance leases | — | 1,885 | 2,121 | 2,235 |
| Net debt (negative means net cash) | — | 1,878 | 2,083 | 2,110 |
| Net debt to EBITDA | — | 4.5x | 13.3x | 8.2x |
| Debt to equity | — | — | — | — |
| Interest coverage | 0.8x | 1.2x | 0.0x | 0.5x |
| Current ratio | — | 0.7x | 0.9x | 1.0x |
| Quick ratio | — | 0.3x | 0.4x | 0.6x |
Cash flow
Projections
Project Calumet's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Calumet shares on the open market, and 2 insiders sold $20.7 million, $267,381 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Daniel J SajkowskiDirector | Sold plan | 4,240 | $36.16 | $153,318 | Form 4 |
| May 15, 2026 | Heritage Group10% owner | Sold | 626,998 | $32.54 | $20.4 million | Form 4 |
| Apr 1, 2026 | Daniel J SajkowskiDirector | Sold plan | 3,310 | $34.46 | $114,063 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | 5 of 9 |
| Rule of 40 | −17.6% | −2.7% | 0.1% |
| Altman Z'' | — | −2.26 | −1.84 |
| Accruals ratio | — | −6.4% | −5.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | — | — | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | Fail |
| Current ratio rose | — | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | 5 of 9 |
Compare
Put Calumet side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Calumet | FY25 | −1.2% | 2.6% | 1.4% | 6.2% | 8.2x | 5 | |
| Delek US | FY25 | −9.5% | 2.8% | 0.1% | 10.4% | 3.8x | 5 | Compare |
| Suncor Energy | FY25 | −4.6% | — | — | 12.5% | — | — | Compare |
| Eni | FY25 | −7.5% | 6.1% | 5.6% | 3.3% | 1.6x | — | Compare |
| Equinor | FY25 | 2.6% | 23.8% | 5.6% | 25.1% | 0.3x | — | Compare |
4 years of figures
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 4,686 | 4,181 | 4,189 | 4,137 |
| Revenue growth | — | −10.8% | 0.2% | −1.2% |
| Gross profit | 352 | 452 | 231 | 246 |
| Research and development | — | — | — | — |
| Operating income | 132 | 267 | 8 | 109 |
| Net income | −173 | 48 | −222 | −34 |
| Diluted EPS (US$) | — | — | −2.67 | −0.39 |
| Diluted shares (millions) | 79 | 80 | 83 | 87 |
| Cash flow | ||||
| Cash from operations | 101 | −15 | −46 | 109 |
| Capital expenditure | 536 | 272 | 77 | 52 |
| Free cash flow | −436 | −287 | −123 | 57 |
| Dividends paid | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Stock-based compensation | 17 | 15 | 15 | −4 |
| Balance sheet at fiscal year end | ||||
| Cash and short-term investments | 35 | 8 | 38 | 125 |
| Debt incl. finance leases | — | 1,885 | 2,121 | 2,235 |
| Total assets | — | 2,751 | 2,758 | 2,689 |
| Total liabilities | — | 2,996 | 3,224 | 3,176 |
| Shareholders' equity | −533 | −490 | −712 | −733 |
| Margins and ratios | ||||
| Gross margin | 7.5% | 10.8% | 5.5% | 5.9% |
| Operating margin | 2.8% | 6.4% | 0.2% | 2.6% |
| Net margin | −3.7% | 1.1% | −5.3% | −0.8% |
| Free cash flow margin | −9.3% | −6.9% | −2.9% | 1.4% |
| Rule of 40 (growth + FCF margin) | — | −17.6% | −2.7% | 0.1% |
| Return on capital | — | — | 0.5% | 6.2% |
| Return on equity | — | — | — | — |
| Return on assets | — | — | −8.1% | −1.2% |
| Net debt to EBITDA | — | 4.5x | 13.3x | 8.2x |